Thomas Trimarchi insider trades: BridgeBio Pharma (BBIO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | BBIO | ↓ Sell | 13,651 | $65.08 | $888K | Direct | May 19, 2026 (1d) |
| Feb 17, 2026 | BBIO | ↓ Sell | 13,600 | $74.72 | $1.0M | Direct | Feb 18, 2026 (1d) |
| Nov 17, 2025 | BBIO | ↓ Sell | 16,934 | $66.46 | $1.1M | Direct | Nov 18, 2025 (1d) |
| Aug 21, 2025 | BBIO | ↓ Sell | 42,237 | $49.48 | $2.1M | Direct | Aug 22, 2025 (1d) |
| Aug 18, 2025 | BBIO | ↓ Sell | 17,353 | $50.23 | $872K | Direct | Aug 19, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BBIO insiders
Open-market trades in the last 12 months
About Thomas Trimarchi's insider trades
Thomas Trimarchi is President and CFO at BridgeBio Pharma (BBIO). Since Aug 18, 2025, Thomas has reported no open-market purchases and 5 sales worth $6.0M on SEC Form 4. In the last 12 months: 3 sales ($3.0M).
Their filings also include shares withheld for taxes (10 filings), grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.